Assessing interactions between common genetic variant on 2q35 and hormone receptor status with breast cancer risk: evidence based on 26 studies.

Genome-wide association studies have identified 2q35-rs13387042 as a new breast cancer (BC) susceptibility locus in populations of European descent. Since then, the relationship between 2q35-rs13387042 and breast cancer has been reported in various ethnic groups; however, these studies have yielded...

Full description

Bibliographic Details
Main Authors: Tao Huang, Jun Hong, Wanlong Lin, Qungqing Yang, Keliang Ni, Qingyu Wu, Jie Sun
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3745398?pdf=render
id doaj-8a9e50ea15694040ac71bce538288cdb
record_format Article
spelling doaj-8a9e50ea15694040ac71bce538288cdb2020-11-25T01:20:11ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0188e6905610.1371/journal.pone.0069056Assessing interactions between common genetic variant on 2q35 and hormone receptor status with breast cancer risk: evidence based on 26 studies.Tao HuangJun HongWanlong LinQungqing YangKeliang NiQingyu WuJie SunGenome-wide association studies have identified 2q35-rs13387042 as a new breast cancer (BC) susceptibility locus in populations of European descent. Since then, the relationship between 2q35-rs13387042 and breast cancer has been reported in various ethnic groups; however, these studies have yielded inconsistent results. To investigate this inconsistency, we performed a meta-analysis of 26 studies involving a total of 101,529 cases and 167,363 controls for 2q35-rs13387042 polymorphism to evaluate its effect on genetic susceptibility for breast cancer. An overall random effects odds ratio of 1.14 (95% CI: 1.11-1.16, P<10⁻⁵) was found for rs13387042-A variant. Significant results were also observed using dominant (OR = 1.14, 95% CI: 1.12-1.17, P<10⁻⁵), recessive (OR = 1.17, 95% CI: 1.13-1.21, P<10⁻⁵) and co-dominant genetic model (heterozygous: OR = 1.15, 95% CI: 1.12-1.19, P<10⁻⁵; homozygous: OR = 1.20, 95% CI: 1.15-1.24, P<10⁻⁵). There was strong evidence of heterogeneity, which largely disappeared after stratification by ethnicity. Significant associations were found in East Asians, and White populations when stratified by ethnicity; while no significant associations were observed in Africans and other ethnic populations. An association was observed for both ER-positive (OR = 1.17, 95% 1.15-1.19; P<10⁻⁵) and ER-negative disease (OR = 1.08, 95% CI: 1.04-1.13; P<10⁻⁴) and both progesterone receptor (PR)-positive (OR = 1.18, 95% CI: 1.15-1.21; P<10⁻⁵) and PR-negative disease (OR = 1.10, 95% CI: 1.05-1.15; P<10⁻⁴). In conclusion, this meta-analysis demonstrated that the A allele of 2q35-rs13387042 is a risk factor associated with increased breast cancer susceptibility.http://europepmc.org/articles/PMC3745398?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Tao Huang
Jun Hong
Wanlong Lin
Qungqing Yang
Keliang Ni
Qingyu Wu
Jie Sun
spellingShingle Tao Huang
Jun Hong
Wanlong Lin
Qungqing Yang
Keliang Ni
Qingyu Wu
Jie Sun
Assessing interactions between common genetic variant on 2q35 and hormone receptor status with breast cancer risk: evidence based on 26 studies.
PLoS ONE
author_facet Tao Huang
Jun Hong
Wanlong Lin
Qungqing Yang
Keliang Ni
Qingyu Wu
Jie Sun
author_sort Tao Huang
title Assessing interactions between common genetic variant on 2q35 and hormone receptor status with breast cancer risk: evidence based on 26 studies.
title_short Assessing interactions between common genetic variant on 2q35 and hormone receptor status with breast cancer risk: evidence based on 26 studies.
title_full Assessing interactions between common genetic variant on 2q35 and hormone receptor status with breast cancer risk: evidence based on 26 studies.
title_fullStr Assessing interactions between common genetic variant on 2q35 and hormone receptor status with breast cancer risk: evidence based on 26 studies.
title_full_unstemmed Assessing interactions between common genetic variant on 2q35 and hormone receptor status with breast cancer risk: evidence based on 26 studies.
title_sort assessing interactions between common genetic variant on 2q35 and hormone receptor status with breast cancer risk: evidence based on 26 studies.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Genome-wide association studies have identified 2q35-rs13387042 as a new breast cancer (BC) susceptibility locus in populations of European descent. Since then, the relationship between 2q35-rs13387042 and breast cancer has been reported in various ethnic groups; however, these studies have yielded inconsistent results. To investigate this inconsistency, we performed a meta-analysis of 26 studies involving a total of 101,529 cases and 167,363 controls for 2q35-rs13387042 polymorphism to evaluate its effect on genetic susceptibility for breast cancer. An overall random effects odds ratio of 1.14 (95% CI: 1.11-1.16, P<10⁻⁵) was found for rs13387042-A variant. Significant results were also observed using dominant (OR = 1.14, 95% CI: 1.12-1.17, P<10⁻⁵), recessive (OR = 1.17, 95% CI: 1.13-1.21, P<10⁻⁵) and co-dominant genetic model (heterozygous: OR = 1.15, 95% CI: 1.12-1.19, P<10⁻⁵; homozygous: OR = 1.20, 95% CI: 1.15-1.24, P<10⁻⁵). There was strong evidence of heterogeneity, which largely disappeared after stratification by ethnicity. Significant associations were found in East Asians, and White populations when stratified by ethnicity; while no significant associations were observed in Africans and other ethnic populations. An association was observed for both ER-positive (OR = 1.17, 95% 1.15-1.19; P<10⁻⁵) and ER-negative disease (OR = 1.08, 95% CI: 1.04-1.13; P<10⁻⁴) and both progesterone receptor (PR)-positive (OR = 1.18, 95% CI: 1.15-1.21; P<10⁻⁵) and PR-negative disease (OR = 1.10, 95% CI: 1.05-1.15; P<10⁻⁴). In conclusion, this meta-analysis demonstrated that the A allele of 2q35-rs13387042 is a risk factor associated with increased breast cancer susceptibility.
url http://europepmc.org/articles/PMC3745398?pdf=render
work_keys_str_mv AT taohuang assessinginteractionsbetweencommongeneticvarianton2q35andhormonereceptorstatuswithbreastcancerriskevidencebasedon26studies
AT junhong assessinginteractionsbetweencommongeneticvarianton2q35andhormonereceptorstatuswithbreastcancerriskevidencebasedon26studies
AT wanlonglin assessinginteractionsbetweencommongeneticvarianton2q35andhormonereceptorstatuswithbreastcancerriskevidencebasedon26studies
AT qungqingyang assessinginteractionsbetweencommongeneticvarianton2q35andhormonereceptorstatuswithbreastcancerriskevidencebasedon26studies
AT keliangni assessinginteractionsbetweencommongeneticvarianton2q35andhormonereceptorstatuswithbreastcancerriskevidencebasedon26studies
AT qingyuwu assessinginteractionsbetweencommongeneticvarianton2q35andhormonereceptorstatuswithbreastcancerriskevidencebasedon26studies
AT jiesun assessinginteractionsbetweencommongeneticvarianton2q35andhormonereceptorstatuswithbreastcancerriskevidencebasedon26studies
_version_ 1725134986447683584